Williams Mullen

 

05.06.2011 James M. Burns Comments on Federal Trade Commission Report Jim Burns was recently interviewed by the BNA Pharmaceutical Law and Industry Reporter regarding the Federal Trade Commission's May 3 report on "pay for delay" drug patent settlements. In the publication's May 6 issue, Jim notes that the FTC's report will likely bolster its efforts to obtain a legislative prohibition on such settlements, which the FTC claims are anticompetitive and have cost consumers billions in increased drug costs. The FTC's focus on a legislative solution follows its lack of success in challenging these settlements in the courts. A link to the article can be found here.